Alcantara Marion, Du Rusquec Pauline, Romano Emanuela
Center for Cancer Immunotherapy, INSERM U932, Institut Curie, PSL Research University, Paris, France.
Dpt of Drug Development and Innovation, Institut Curie, Paris, France.
Oncoimmunology. 2020 Jun 10;9(1):1777064. doi: 10.1080/2162402X.2020.1777064.
Immunotherapy by chimeric antigen receptor (CAR)-modified T-cells has shown unprecedented clinical efficacy for hematological malignancies. Recently two CAR T-cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) were approved by the US Food and Drug Administration and by the European Medicines Agency. Despite the progress in treating hematological malignancies, challenges remain for the use of CAR T-cell therapy in patients with solid tumors. Barriers yet to overcome for achieving effective CAR T-cell therapy include antigenic heterogeneity of solid tumors, an immune-suppressive microenvironment, and organ-specific properties that limit T-cell entry. This review will summarize available clinical data for CAR T-cell therapy in solid tumors, including present obstacles and promising strategies to advancement.
嵌合抗原受体（CAR）修饰的T细胞免疫疗法已在血液系统恶性肿瘤中展现出前所未有的临床疗效。最近，两种基于CAR T细胞的疗法，即Kymriah（tisagenlecleucel）和Yescarta（axicabtagene ciloleucel）分别获得了美国食品药品监督管理局和欧洲药品管理局的批准。尽管在治疗血液系统恶性肿瘤方面取得了进展，但CAR T细胞疗法在实体瘤患者中的应用仍面临挑战。实现有效的CAR T细胞疗法尚需克服的障碍包括实体瘤的抗原异质性、免疫抑制微环境以及限制T细胞进入的器官特异性特性。本综述将总结CAR T细胞疗法在实体瘤中的现有临床数据，包括当前的障碍和有前景的推进策略。
